MEDIA ADVISORY: Foxit to Attend EDUCAUSE 2025

Discover how Foxit's intelligent PDF and eSignature tools help educators, administrators, and students simplify workflows, boost collaboration, and accelerate digital learning Foxit, a leading provider of innovative PDF and eSignature products and services that help knowledge workers increase productivity and do more with documents, will showcase its latest education-focused document solutions at EDUCAUSE 2025. https://mma.prnewswire.com/media/2620217/new_foxit_Logo_2025.jpg […]

Revalesio to Present RNS60 !!!!12-Hour Data from the Phase 2 RESCUE Trial in Acute Ischemic Stroke at World Stroke Congress 2025

Revalesio, a clinical-stage pharmaceutical company pioneering neuroprotective therapies for neurological disorders, today announced that data from a post hoc analysis of the RESCUE Phase 2 clinical trial of its investigational drug RNS60 will be featured as one of two promising drug candidates for the treatment of stroke in an upcoming session at the 17th World

Talphera Announces the Appointment of Joe Todisco to Board of Directors

Talphera, Inc.(Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (Nasdaq: CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of

New ePlus AI Industry Pulse Poll Reveals Strategic Shift: AI Moves from Efficiency to Expansion

Nearly Three Out of Four IT and Industry Leaders Now Prioritize Revenue Growth as Main Driver of AI Initiatives, Over Cost Savings and Increased Customer Satisfaction ePlus inc. (NASDAQ: PLUS) today announced the findings of its new AI Industry Pulse Poll, which offers a closer look at how organizational leaders are reimagining the role of

RTX Fintech Taps Former Interest Rate Swaps Trader Léger as Chief Product Officer to Drive Platform Innovation

RTX Fintech & Research (“RTX Fintech”), a leading US electronic interdealer trading platform for interest rate swaps, today announced the appointment of André Léger as Chief Product Officer and Head of Markets, Asia. Léger will be responsible for driving RTX's end-to-end product development and global platform roadmap, while enhancing platform functionality through integrated market research

IAB Addresses Changing Market Dynamics, Reinvents its Marketplace Event Schedule

IAB NewFronts Moves to March to Align with Buyer Demand Fall 2026 Lineup Combines IAB PlayFronts, IAB Podcast Upfront, and Launches First-EverIAB CreatorFronts Across a Single Week Today the Interactive Advertising Bureau (IAB), the leading trade body for the digital advertising industry, unveiled strategic changes to its 2026 calendar of marketplace events, reinforcing its commitment

Beyond the bench: The advantages of GMP over USP compounding in early phase development, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insights about the differences between GMP and USP compounding in research. Attendees will learn that although USP can support certain research needs, it falls short when robust data integrity, reproducibility and regulatory compliance are required, particularly in early phase clinical trials. The featured speakers will share real-world case studies, where

Kaya Holdings, Inc. Releases Update on Development of Cryptocurrency Subsidiary and Digital Assets Treasury

FT. LAUDERDALE, FL, 2654 / ACCESS Newswire / October 21, 2025 / Kaya Holdings, Inc. (OTCQB:KAYS) (the "Company" or "KAYS") confirmed that its newly formed cryptocurrency operating subsidiary is conducting ongoing discussions with cryptocurrency foundations and other entities/individuals through its representatives Thomas Gaffney of Conduit Advisors ("Thomas") and the team at Greentree Financial Group ("Greentree")

Improving Translational Research and Clinical Trials with Digital Pathology, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how expert-led pathology supports translational research and clinical trials at every stage. Attendees will gain insight into how expert pathology leadership supports trial design and execution. The featured speaker will discuss the role of digital pathology in enabling faster turnarounds and global collaboration. Attendees will also understand why pathology should

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout GlobeNewswire October 21, 2025 MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) — Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics,

Scroll to Top